Cultured human endothelial cells produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF) when stimulated with human thrombin. The response to thrombin is dose dependent, with a half-maximal effect at 0.17 unit/ml. The product is identified as PAF by the incorporation of radiolabeled precursors, its behavior in chromatographic systems, the recovery of biological activity, and the effect of treatment with phospholipase A2. Incorporation of [3Hjacetate into PAF is maximal by 5 min and decreases thereafter. Endothelial cells produce 0.10-0.17 nmol of PAF per 106 cells in a 5-min exposure to thrombin, as judged by the amount of neutrophil-aggregating activity. The production of this potent agonist for platelet activation and neutrophil chemotaxis by endothelial cells suggests that it may play a role in the maintenance of vascular integrity and perhaps in pathological events such as thrombosis and atherogenesis.
als have been associated with pathological events, including thrombosis and atherogenesis (2, 7) . The mechanism for the loss of the nonthrombogenic properties of endothelium is unknown, but presumably the loss could result from the production of a thrombogenic substance by endothelium.
Platelet-activating factor (PAF) is a potent stimulus for platelet aggregation and neutrophil aggregation and chemotaxis (8) . The chemical identity of PAF has been shown to be 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by Demopoulos and co-workers (9, 10), and its biosynthesis (11) (12) (13) , degradation (14, 15) , and effects on other cells and tissues (16) (17) (18) (19) (20) have been extensively investigated recently. We have examined cultured human endothelial cells for production of PAF since such a response could explain the increased interaction of endothelium with platelets and neutrophils under some physiological and pathological circumstances. We demonstrate here that endothelial cells produce PAF when stimulated with thrombin, an agent that is known to increase platelet adhesion to endothelium (21 Culture of Endothelial Cells. We used a modification of the methods of Jaffe et al. (22) . The cells were cultured in medium 199 containing 25 mM Hepes buffer, supplemented with L-glutamine (2.0 mM), penicillin (100 units/ml), streptomycin (100 ttg/ml), and 20% pooled human serum. The cultures, on 35-mm gelatin-coated plates, reached confluency in 5 days, at which time the plates were completely covered by uniform, contact-inhibited monolayers of flattened, closely apposed endothelial cells. Under these conditions there were 7.6 x 105 endothelial cells per plate (9.4 x 104 cells per cm2 of surface area). Contamination by smooth muscle cells, fibroblasts, or other cells was estimated by microscopy to be less than 0.2% in all cultures used. The identity of endothelial cells grown in this fashion was verified by morphology and demonstration of factor VIII antigen by indirect immunofluorescence. Endothelial isolates from six veins were used for these experiments.
Assay of [3HjAcetate Incorporation into PAF. This assay was performed as described by Mueller et al. (13) 
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Another portion was dissolved in 1.0 ml of diethyl ether and treated with phospholipase A2 from Crotalus adamanteus as described (25) . Control incubations received no enzyme. The extracts of these incubations were analyzed by TLC as above.
Metabolism of 1-[3H]Alkyl-sn-glycero-3-phosphocholine (1- [3H]Alksyl-GroPCho). 1-[3H]alkyl-GroPCho was generated from [ H]PAF by saponification in 0.12 M NaOH in CHC13/MeOH (1:4, vol/vol) for 10 min at 370C and was purified by TLC (above). Endothelial cells were labeled with 1.5 ,uCi of 1-[3H]alkyl-GroPCho (dissolved in 0.5 ml of medium) for 4 hr at 370C. The labeling medium was removed and replaced with regular culture medium containing either no additions or human thrombin (2 units/ml). After 5 min the reaction was terminated, and the cells were scraped from the plate and extracted in solvent that contained 10 nmol each of 1-alkyl-GroPCho and PAF. A portion of the lipid extract was taken for direct scintillation spectrometry and the remainder was applied to a TLC plate for separation and quantitation as described above. In these experiments, 1-alkyl-GroPCho and PAF were clearly separated (Rf = 0.13 and 0.21, respectively) and in the labeling experiments an intermediate area did not contain radioactivity above background.
Recovery of Biological Activity. Six dishes of endothelial cells were stimulated for 5 min with thrombin at 2 units/ml and extracted as described above (without carrier PAF). The extract was applied to the HPLC system and 0.5-ml fractions of the effluent were collected. The fractions were dried under nitrogen, redissolved in 75 ptl of 0.15 M NaCi that contained fatty acid-free bovine serum albumin at 1 mg/ml, and tested as described below. After the separation of the unknown sample, 5 nmol of unlabeled authentic PAF was applied to the HPLC and the resultant fractions were handled in the same way as the unknown except that each was redissolved in 0.5 ml.
To estimate the quantity of PAF from endothelial cells, portions from each fraction found to contain bioactivity were combined and dilutions of the resultant solution were assayed for PMN-aggregating activity. A portion of the combined product was treated with phospholipase A2 (as above) and compared with another portion that had been treated with buffer for biological activity.
Granulocyte and Platelet Aggregometry. The method of Craddock et al. (26) was used to examine purified products of stimulated endothelial cells for PMN-aggregating activity. Isolated human PMNs, 0.55 x 107 cells per ml, in HBSS with human albumin at 5 mg/ml, were treated with cytochalasin B (5 ,ug/ml) for 15 min at 37°C. Aggregometry was performed by stirring (900 rpm) 0.45 ml of the PMN solution in a Payton (Buffalo) model 300 BD aggregometer at 37°C for 2 min and then adding 50 ,4 of the solution to be tested. Light transmission (T) was monitored and recorded on a strip chart continuously for 3-5 min. The maximal AT, excluding the dilution artifact, induced by each sample was measured. Under the conditions of these experiments, the maximal AT is proportional to the area under the aggregation curve. Human platelets were prepared and their aggregation (27) and serotonin release (28) were measured as described.
PMN Adherence to Endothelial Cells. Duplicate endothelial cell monolayers were incubated with thrombin (Sigma) at 0.5 units/ml for 2 min at 37°C. The supernatant solutions were removed and replaced with suspensions of isolated PMNs (5.5 x 106/ml). Adherence of PMNs was measured by removing the supernatant, after 15 min, and determining the number of PMNs remaining in suspension (29 (Fig. 1) . When incorporation by stimulated cells was compared to controls, there was a clear increase in the amount of radiolabel recovered in the fraction with the same Rf as authentic PAF in the thrombin-treated cells. Cells from each isolate demonstrated this response. The time course of acetate incorporation into this lipid showed the effect to be maximal by 5 min (Fig. 2) , with a subsequent slow loss of label. The response to thrombin was concentration dependent (Fig. 3) (Table 2) . Small quantities of the latter were found even in monolayers that had not been exposed to thrombin, although some aspect of the incubation conditions may have stimulated them. The addition of thrombin resulted in an increase in both the absolute amount and percentage of radiolabel found in the PAF-containing fraction of the TLC (Table 2) (Fig. 3) . Active thrombin is required, as is the presence of divalent cations, and the PAF that is produced remains associated with the cells under the conditions of our experiments ( Table 1) .
The production of PAF previously has been described in blood cells (10, 13, 31) and macrophages (32) , and PAF has been found in amniotic fluid (33) . In addition to its effects on inflammatory cells, PAF has been shown to affect smooth muscle preparations (18) and pulmonary function (19) and to stimulate glucose production by perfused liver (20) . Whether endothelial cell-derived PAF plays a role in these effects is uncertain. The finding that this potent stimulus for platelet and PMN activation is synthesized by endothelial cells may explain the increased adherence of these blood cells to endothelium under some circumstances. For example, the perfusion of isolated umbilical veins with a solution of thrombin followed by perfusion with platelet-rich plasma led to increased platelet adherence to endothelial cells when compared to controls (21) the endothelial lining, and the production of PAF by endothelial cells may promote platelet adhesion as a means of maintaining vascular integrity under such conditions. However, augmented production of PAF, generated by stimuli that injure the endothelium, could result in thrombosis or amplify the response to endothelial injury. The latter possibility suggests that PAF production by endothelial cells may play a role in atherogenesis or syndromes of vascular injury mediated by platelets or PMNs.
While this manuscript was under review Camussi et al. reported the production of PAF by cultured endothelial cells (35) . Their results differ from those reported here in that they found no response to thrombin unless it was added repeatedly, and they found PAF to be released into the supernatant buffer.
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